CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Merck Sharp & Dohme Corp. v. Ben Venue Laboratories Inc.

1:13-cv-01611

πŸ“‘ 5G SEP β€’ ETSI Declared

Overview

Case Number 1:13-cv-01611
Filing Date 2013-09-25
Status Terminated
Termination Date 2014-02-11
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Ben Venue Laboratories Inc. Operating Company

Represented By

1 Attorneys Listed

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Plaintiff

Millennium Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Merck Sharp & Dohme Corp. Operating Company

Represented By

2 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 2 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (2 found):
U.S. Courts: 2
U.S. District Court 2013-01-31
1:13-cv-00166

Merck Sharp & Dohme Corp. v. APP Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-11-09
1:12-cv-01410

Merck Sharp & Dohme Corp. v. APP Pharmaceuticals Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP β€’ ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

βœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
βœ“ Right to demand global FRAND portfolio determination.
βœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5807825
Platelet aggregation inhibitors
Filed: 1995-06-07
Issued: 1998-09-15
Expired (Term Ended)
Expires: 2015-06-07
US5747447
Stable polypeptide composition
Filed: 1995-06-05
Issued: 1998-05-05
Expired (Term Ended)
Expires: 2015-06-05
US5968902
Platelet aggregation inhibitors
Filed: 1995-06-07
Issued: 1999-10-19
Expired (Term Ended)
Expires: 2015-06-07

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 8 STIPULATION TO EXTEND TIME to Respond to the Complaint to February 21, 2014, filed by Ben Venue Laboratories Inc. (Reset Answer Deadlines: Ben ...
Entry #β€” • 2014-02-04
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Respond to the Complaint to February 21, 2014 - filed by Ben Venue Laboratories Inc.. (Keller, Karen) (Entered: 02/03/2014)
Entry #8 • 2014-02-03 Document →

Docket Entries

(14 total)
Pleading / Complaint

COMPLAINT filed against Ben Venue Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1374859.) - filed by Millennium Pharmaceuticals Inc., Merck Sharp & Dohme Corp.. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(cla, ) (Entered: 09/25/2013)

Entry #1 • 2013-09-25
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cla, ) (Entered: 09/25/2013)

Entry #2 • 2013-09-25
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/16/13. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 9/15/2015. (cla, ) (Entered: 09/25/2013)

Entry #3 • 2013-09-25
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,807,825; 5,747,447; 5,968,902;. (cla, ) (Entered: 09/25/2013)

Entry #4 • 2013-09-25
1

Disclosure Statement pursuant to Rule 7.1 filed by Merck Sharp & Dohme Corp. identifying Corporate Parent Merck & Co Inc. for Merck Sharp & Dohme Corp.. (cla, ) (Entered: 09/25/2013)

Entry #5 • 2013-09-25
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc